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Abstract
Objectives Recently a novel subgroup of bronchiolitis
obliterans syndrome (BOS) has been described in patients
after lung transplantation with high neutrophil counts in
broncho-alveolar lavage and recovery of lung functional
decline with azithromycin treatment. We aimed to describe
the thin-section computed tomography (CT) findings of
these neutrophilic reversible allograft dysfunction (NRAD)
patients before and after azithromycin.
Methods A cohortof100lungtransplantrecipientswithBOS
were treated with azithromycin and underwent lung function
testing, broncho-alveolar lavage and CT before azithromycin
treatment and during follow-up. The 200 CT data sets were
scored for bronchial dilatation, mucus plugging, centrilobular
abnormalities, airway wall thickening, consolidation, ground
glass and end-expiratory air trapping.
Results NRAD was characterized by more centrilobular
abnormalities on CT (p=0.03 for prevalence and p=0.06
for severity) compared to non-responders. At follow-up
NRAD patients showed improvement in all CT abnormal-
ities including air trapping, but the degree of improvement
in all CT abnormalities was significantly different between
responders and non-responders (who showed progression
of bronchus dilatation, consolidation and air trapping).
Conclusions Within BOS patients those with NRAD differ
from azithromycin non-responders by more centrilobular
abnormalities on CT before azithromycin and improvement
in bronchus dilatation, consolidation and air trapping during
treatment.
Keywords Computed tomography.Azithromycin.
Bronchiolitis obliterans syndrome.Chronic allograft
rejection.Neutrophilic broncho-alveolar lavage
Key points
1. Bronchiolitis obliterans syndrome was considered
irreversible in chronic lung transplant rejection
2. Recently, neutrophilic reversible allograft dysfunction
(NRAD), was recognized as a treatable form
3. Computed tomography can demonstrate specific abnor-
malities in these patients
4. Computed tomography may aid physicians in early and
accurate diagnosis of NRAD
Introduction
The main obstacle to long-term survival of lung transplant
recipients is the development of bronchiolitis obliterans
syndrome (BOS) [1]. BOS is characterized by a progressive
decline in the forced expiratory volume in one second (FEV1)
for which no explanation such as infection or bronchus
stenosis can be found. The syndrome BOS is introduced to
describe chronic allograft rejection in the absence of
histological proof of obliterative bronchiolitis. Indeed, classi-
cally it is thought that the dysfunction is caused by an
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ically characterized by fibroproliferative damage to the small
airways. The radiological feature of this fibroproliferative
form of BOS has been described as extensive air trapping
(>32% of the lung had to be involved) on end-expiratory CT
in patients with normal inspiratory CT findings [2].
Important recent observations revealed that the graft
dysfunction is not always irreversible, but there exists an
important subgroup of BOS patients who respond to azithro-
mycin treatment [3]. These patients typically have extensive
neutrophils in the broncho-alveolar lavage fluid and this new
entity was called neutrophilic reversible allograft/airways
dysfunction (NRAD) [3]. NRAD is strictly defined as an
increase in FEV1 ≥10% after 3 to 6 months of azithromycin
treatment (compared to FEV1 at start of treatment, based on
two separate measurements with at least 3 weeks in between).
Several groups [4–9] confirmed these observations and
nowadays there is convincing evidence for the existence of
NRAD [5, 9]. However, the radiological findings have not
been described systematically [3, 10]. Knowledge about the
presentation of NRAD on CT images would be important as
not all patients respond to azithromycin and CT might be
valuable in the diagnosis and treatment of this disease entity.
We aimed to describe the CT findings in patients with
bronchiolitis obliterans syndrome either with or without
neutrophilic reversible allograft dysfunction before and
after azithromycin treatment.
Methods
Subjects
We studied a retrospective cohort of 100 lung transplant
recipients that was selected in a single centre as follows.
Between July 1991 and January 2009 463 lung transplanta-
tions were performed. Patients who were never treated with a
macrolide (n=216), who were treated with a macrolide for
other reasons than chronic lung allograft dysfunction (n=56)
or who participated in a placebo-controlled azithromycin trial
(n=83) were excluded. When the present study was
designed, the trial was not unblinded, therefore these subjects
were excluded. From the remaining 108 patients 1 was
excluded because of follow-up less than 3 months and 7
were excluded because of missing CT data at the start of
treatment and/or during follow-up. The resulting 100 patients
were all treated with azithromycin for chronic lung allograft
dysfunction. Treatment was following our clinical protocol
starting with 250 mg azithromycin per day for the first
5 days and subsequently 250 mg azithromycin on Monday,
Wednesday and Friday. The study was approved by the local
University Hospital Ethical Review Board and all patients
gave written informed consent.
CT protocol
The CT examinations were performed on a Siemens
Somatom Sensation 16 or 64, a Siemens Definition Flash
(Siemens AG, Erlangen Germany) or a Philips Brilliance 64
(Philips Medical Systems, Best, The Netherlands) without
intravascular contrast media. One CT data set of the entire
thorax was obtained in suspended deep inspiration in the
supine position using 120 kV and 140 mAs and recon-
structed as follows: 1/0.5 mm axial, 5/5 mm axial and 3/
3 mm coronal displayed in lung and mediastinal window-
centre settings. Another CT data set was also obtained after
breath-hold instruction at end- expiration with the patient
supine but in a sequential mode with collimation 2×1 mm
and table feed of 30 mm using 120 kV and 150 mAs.
Reconstructions of 1 mm slice thickness were calculated
and displayed in lung window-centre settings.
CT scoring
The resulting 200 CT data sets in 100 patients were scored
by using a previously described system [11]. This system
semi-quantitatively scores on inspiratory CT the severity
and extent of bronchus dilatation in the central and
peripheral lung, extent of mucous plugging in large
airways, extent of centrilobular nodules including tree-in-
bud, extent and severity of airway wall thickening in the
central and peripheral lung, extent of consolidation and
extent of ground glass opacities and extent of air trapping
on expiratory CT. In general abnormalities were defined
according to the Fleischner Society nomenclature [12].
More specifically, bronchus dilatation was defined as a
bronchus lumen diameter greater than the accompanying
pulmonary artery outer diameter, lack of tapering of the
bronchus or bronchi visible in the outer centimeter of the
lung. Airway wall thickening was defined as a wall
thickness to artery diameter ratio >0.2, this was assessed
subjectively [13]. Each abnormality was scored in six lung
lobes (lingula included), and per lobe the extent involved
with the abnormality was estimated as less than one-third,
between one-third and two-thirds, and more than two-thirds
of the lobar volume. All scores presented are expressed on a
scale 0–100 as previously described because this scale may
enable easier interpretation. For example when one of six
lobes demonstrated centrilobular changes and that lobe was
involved with this abnormality for more than two-thirds, the
centrilobular score would be 100*((0+0+0+0+0+2)/18)=
11%, with 18 being the maximum possible score for that
item. The CT score can thus be interpreted as a percentage
of the lung being involved. CT data sets were scored by one
observer for whom the reproducibility has previously been
described [11]. CT examinations were scored independently
in random order, but the observer was not blinded to
Eur Radiol (2011) 21:2466–2474 2467baseline or post-treatment status. The observer was blinded
for patient characteristics including neutrophil count and
azithromycin response. Both coronal and axial images
could be used for scoring.
Other investigations
Broncho-alveolar lavage (BAL) was routinely performed, if
possible, around fixed time points after lung transplantation
(21 days, 3, 6, 12, 18, 24, 30 months, 3, 4, 5 years), or if acute
rejection, infection or BOS was suspected. BAL fluid was
evaluated for neutrophil% and was cultured for pathogenic
organisms. Neutrophil counts were obtained at baseline in 34
(83%) responders and 47 (80%) non-responders and at follow-
up in 29 (71%) responders and 43 (73%) non-responders.
Spirometry was performed in agreement with American
Thoracic Society-criteria, prior to bronchoscopy (Master-
screen, Jaeger, Germany) [14]. BOS was diagnosed and
staged according to the The International Society for Heart
and Lung Transplantation (ISHLT)-working formulation [1].
Response to azithromycin was defined as an increase in FEV1
≥10% after 3 to 6 months of treatment (compared to FEV1 at
start of treatment, based on two separate measurements with
at least 3 weeks in between) and non-responders were defined
as having an increase of less than 10%.
Data analysis
Responders were compared to non-responders by using
Mann–Whitney-U test for continuous variables and Chi-
square statistics for categorical variables. SPSS 18.0 (Inc.
Chicago, IL, USA) was used for data analysis. Improve-
Table 1 Characteristics of 100 lung transplant recipients with allograft dysfunction who were treated with azithromycin
Patients responding to
azithromycin (NRAD)
Patients not responding
to azithromycin
Difference
between groups
N=41 N=59 p-value
Age in years; Median (25%–75%) 52.0 (40.5–59.0) 49.0 (29.0–56.0) 0.30
Gender male; N (%) 21 (52) 31 (53) 0.90
Single lung transplant; N (%) 12 (29) 20 (34) 0.63
Years after lung transplant of start allograft dysfunction; Median
(interquartile range)
1.81 (0.59–3.82) 3.03 (1.33–5.19) 0.09
Months between CT Median (interquartile range) 7.0 (4.6–11.5) 8.1 (4.8–11.9) 0.39
Neutrophils% in broncho-alveolar lavage; Median (interquartile range) 29.3 (10.4–69.2) 12.8 (3.0–44.0) 0.04
Neutrophils% after azithromycin; Median (interquartile range) 6.0 (1.9–46.5) 10.4 (2.8–44.2) 0.37
FEV1% before treatment; Median (interquartile range) 67.0 (52.0–82.5) 60.0 (46.0–76.0) 0.10
FEV1% at follow-up; Median (interquartile range) 82.0 (64.5–99.0) 52.0 (38.0–73.0) <0.0001
N=Number, FEV1=Forced expiratory volume in one second. Between group differences are tested with Mann–Whitney-U test for continuous
variables and Chi-square statistics for categorical variables. NRAD: neutrophilic reversible allograft dysfunction. Neutrophil counts were obtained
at baseline in 34 (83%) responders and 47 (80%) non-responders and at follow-up in 29 (71%) responders and 43 (73%) non-responders
Table 2 Prevalence of thin-section CT findings in lung transplant recipients with allograft dysfunction before start of azithromycin treatment
Patients responding
to azithromycin
(NRAD)
Patients not responding
to azithromycin
Difference between
groups
N=41 N=59 p-value
Bronchus dilatation N (%) 13 (32) 25 (42) 0.28
Large airway mucus N (%) 10 (24) 13 (22) 0.78
Centrilobular nodules N (%) 22 (54) 19 (32) 0.03
Airway wall thickening N (%) 14 (34) 16 (27) 0.45
Consolidation N (%) 15 (37) 17 (29) 0.41
Ground glass N (%) 17 (42) 20 (34) 0.44
Air trapping N (%) 34 (83) 53 (90) 0.31
Air trapping >32% N (%) 16 (39) 26 (44) 0.62
Between group differences are tested with a Chi-square test; N=number. NRAD: neutrophilic reversible allograft dysfunction
2468 Eur Radiol (2011) 21:2466–2474ment and worsening in CT scores was defined as the post-
treatment score being, respectively, lower and higher when
compared to the pre-treatment CT score. Data are given as
median (interquartile range) unless indicated otherwise and
significance level was set at P<0.05.
Results
Clinical characteristics of responders (NRAD) versus non
responders
Of the 100 subjects 41 responded and 59 did not respond to
azithromycin treatment. Both responders and non-
responders were on average around 50 years of age, a little
over 50% was male and approximately one-third received
single lung transplantation. Clinical characteristics were not
different between the groups, except the expected neutro-
phil percentage in the BAL before treatment which was
significantly higher in the responders and the FEV1 after
treatment which was significantly higher in the responders.
These findings are summarized in Table 1.
Prevalence and severity of CT abnormalities
before azithromycin
Before treatment NRAD responders had more often
centrilobular changes (nodules and tree-in-bud, p=0.03)
and tended to have higher centrilobular scores (p=0.06) in
comparison with non-responders. Bronchus dilatation,
mucous plugging, airway wall thickening, consolidation,
ground glass and air trapping presence and severity were
not different between responders and non-responders at
baseline. These findings are summarized in Tables 2 and 3.
Changes in CT findings after treatment
In azithromycin responders all abnormalities including
bronchus dilatation, mucous plugging, centrilobular
abnormalities airway wall thickening, consolidation,
Table 3 Thin-section CT scores in lung transplant recipients with allograft dysfunction before start of azithromycin treatment
Patients responding
to azithromycin (NRAD)
Patients not responding
to azithromycin
Difference between
groups
N=41 N=59 p-value
Bronchus dilatation; Mean (range) 2.6 (0.0–35.2) 3.1 (0.0–22.2) 0.27
Large airway mucus; Mean (range) 3.7 (0.0–27.8) 3.2 (0.0–33.3) 0.73
Centrilobular nodules; Mean (range) 14.0 (0.0–88.9) 9.1 (0.0–66.7) 0.06
Airway wall thickening; Mean (range) 1.9 (0.0–14.8) 1.7 (0.0–16.7) 0.58
Consolidation; Mean (range) 3.9 (0.0–44.4) 4.1 (0.0–55.6) 0.55
Ground glass; Mean (range) 5.8 (0.0–33.3) 7.1 (0.0–66.7) 0.66
Air trapping; Mean (range) 22.6 (0.0–55.6) 29.5 (0.0–100.0) 0.27
Between group differences are tested with Mann–Whitney-U test. NRAD: neutrophilic reversible allograft dysfunction
Table 4 Longitudinal thin-section CT scores in lung transplant recipients with allograft dysfunction during azithromycin treatment
Patients responding
to azithromycin (NRAD)
Patients not responding
to azithromycin
Difference between
groups
Number=41 Number=59 p-value
Bronchus dilatation; Mean (range) −0.79 (−20.4–0.0) 1.5 (0.0–27.8) <0.0001
Large airway mucus; Mean (range) −2.4 (−27.8–5.6) −0.09 (−33.3–22.2) 0.04
Centrilobular nodules; Mean (range) −10.7 (−88.9–22.2) −2.8 (−55.6–22.2) 0.001
Airway wall thickening; Mean (range) −1.5 (−14.8–3.7) −1.2 (−12.0–4.6) 0.004
Consolidation; Mean (range) −3.0 (−33.3–0.0) 1.0 (−11.1–33.3) 0.004
Ground glass; Mean (range) −4.9 (−33.3–0.0) −0.28 (−33.3–55.6) 0.009
Air trapping; Mean (range) −2.0 (−33.3–38.9) 3.5 (−33.3–55.6) 0.02
Between group differences are tested with Mann–Whitney-U Test. NRAD: neutrophilic reversible allograft dysfunction
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The degree of improvement was for all CT abnormal-
ities significantly different from the degree of change in
the non-responders. In the non-responders some abnor-
malities improved (mucous plugging, centrilobular ab-
normalities, airway wall thickening and ground glass
opacities), but bronchial dilatation, consolidation and air
trapping worsened. These findings are summarized in
Table 4.F i g u r e s1, 2, 3 and 4 demonstrate the improve-
ment in bronchial dilatation, centrilobular abnormalities,
consolidation and air trapping in azithromycin responders.
Figures 5 and 6 demonstrate progressive air trapping in
non-responders with the classical fibroproliferative form
of BOS or constrictive bronchiolitis.
Fig. 1 Longitudinal CT findings in a 15-years old heart-lung
transplant recipient with BOS responding to azythromycin (neutro-
philic reversible allograft dysfunction (NRAD)). Four axial thin-slice
CT images at inspiration before (left) and after (right) treatment with
azithromycin in a patient who responded favorably. The pre-treatment
CT images on the left demonstrate bronchial dilatation, bronchial wall
thickening and centrilobular abnormalities all of which resolved on the
follow-up CT images on the right. The lung allograft dysfunction
occurred 3.2 years after transplantation, neutrophil counts are
unknown. FEV1 had deteriorated 16% from baseline at the start of
treatment and 13% was recovered after 6 months. This patient was
judged to have reversible allograft dysfunction
Fig. 2 Longitudinal CT findings in a 52-years old double lung
transplant recipient with with BOS responding to azythromycin
(neutrophilic reversible allograft dysfunction (NRAD)). Two coronal
thin-slice CT imaging at inspiration before (left) and after (right)
treatment with azithromycin in a patient who did respond. The pre-
treatment CT image demonstrates centrilobular nodules and tree-in-
bud mainly at the apex and base of the right lung, which normalised
on the follow CT. The lung allograft dysfunction occurred 4.2 years
after transplantation, the broncho-alveolar lavage fluid revealed 89.6%
neutrophils. FEV1 had declined to 75% at the start of treatment and
improved to 90% in the subsequent 6 months. This patient was judged
to have neutrophilic reversible allograft dysfunction
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We studied the thin-section CTimaging featuresin a cohortof
lung transplant recipients with bronchiolitis obliterans syn-
drome (BOS) before and after azithromycin treatment. The
BOS patients who did improve—those with neutrophilic
reversible allograft dysfunction or NRAD—had significantly
moreoftencentrilobularabnormalitieswithorwithouttree-in-
bud on the pre-treatment CT. In this group the severity of
bronchus dilatation, mucous plugging, centrilobular abnor-
malities, airway wall thickening, consolidation, ground glass
and air trapping improved significantly more when compared
with the BOS patients who did not improve.
The main obstacle to long-term survival of lung
transplant recipients remains the development of bronchio-
litis obliterans syndrome (BOS). Imaging research has
focused on the thin-section CT features of this syndrome
and whether these features may be able to demonstrate the
syndrome earlier, before lung function deteriorates. It is
indeed thought that only at a very early stage the process of
obliterative bronchiolitis might be halted with intensive
immune-suppression. In general, it is accepted that,
although a variety of abnormalities are seen, air trapping
is the main finding in patients with obliterative bronchiolitis
[15–23] and air trapping involving more than 32% of the
lung was shown to have good accuracy for the diagnosis of
BOS [2]. Whether thin-section CT in lung transplant
recipients is able to detect disease earlier than spirometry
or transbronchial biopsy remains controversial, with some
studies suggesting its value [2, 24], while others could not
Fig. 3 Longitudinal CT findings in a 14-years old double lung
transplant recipient with BOS responding to azythromycin (neutro-
philic reversible allograft dysfunction (NRAD)). Two coronal thin-
slice CT imaging at inspiration before (left) and after (right) treatment
with azithromycin in a patient who did respond. The pre-treatment CT
image demonstrates centrilobular nodules and tree-in-bud and consol-
idation bilateral, which nearly reversed on the follow CT. The lung
allograft dysfunction occurred 0.96 years after transplantation, the
broncho-alveolar lavage fluid revealed 97% neutrophils. FEV1 had
deteriorated 14% from baseline at the start of treatment and recovered
in the subsequent 6 months. This patient was judged to have
neutrophilic reversible allograft dysfunction
Fig. 4 Longitudinal CT
findings in two lung transplant
recipients with BOS responding
to azythromycin (neutrophilic
reversible allograft dysfunction
(NRAD)) who demonstrated a
reduction in the extent of air
trapping on expiratory CT.
Axial thin-slice CT images at
end-expiration before (left)
and after (right) treatment with
azithromycin in two patients
(upper and lower panel) who
did respond to azithromycin.
Air trapping decreased to
some extent on CT which
is inconsistent with
fibroproliferative obliterative
bronchiolitis as this is thought
to be an irreversible process
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paradigm has changed for an important subgroup of BOS
patients as this ‘irreversible’ disease has proven reversible
in a substantial subgroup with azithromycin therapy.
Azithromycin is a macrolide antibiotic which has anti-
bacterial but also a variety of immunomodulatory effects
[25]. These patients are further characterized by extensive
neutrophils in the broncho-alveolar lavage fluid (without
specific pathogens being cultured) and research to determine
the pathogenesis is actively ongoing [26]. In order to
determine whether thin-section CT could have a diagnostic
role in this new disorder, the signs have to be known first.
Therefore the present study is important since we showed
that most CT abnormalities largely overlap between NRAD
patients and non-responders to azithromycin, but that
centrilobular nodules including tree-in-bud are significantly
more common in NRAD patients. For the non-responders
the question still remains whether CT has a role in the early
diagnosis of small airways narrowing in the fibrotic
subgroup of bronchiolitis obliterans syndrome.
We also showed the changes in CT abnormalities under
azithromycin treatment. Especially the improvement in air
Fig. 5 Longitudinal CT findings in a 33-years old double lung
transplant recipient with progressive air trapping whose allograft
dysfunction did not respond to azithromycin therapy. Two axial thin-
slice CT imaging at end-expiration before (left) and after (right)
treatment with azithromycin in a patient who did not respond. The
pre-treatment CT image demonstrates some secondary pulmonary
lobules with air trapping. The follow-up CT image on the right
demonstrates more lobules with air trapping in the medial right lower
lobe and diffuse air trapping in the left lower lobe. The lung allograft
dysfunction occurred 1.4 years after transplantation, the broncho-
alveolar lavage fluid revealed 3.5% neutrophils. FEV1 had declined to
76% at the start of treatment and declined further to 46% in the
subsequent 6 months. This patient was judged to have the original
form of obliterative bronchiolitis
Fig. 6 Longitudinal CT findings in a 29-years old single right lung
transplant recipient with subtle progressive air trapping whose dysfunc-
tion did not respond to azithromycin therapy. Two axial thin-slice CT
images at end-expiration before (left)a n da f t e r( right) treatment with
azithromycin in a patient who did not respond. The pre-treatment CT
image demonstrates about half of the secondary pulmonary lobules with
air trapping. The follow-up CT image on the right demonstrates more
lobules lateral in the lower lobe and more diffuse air trapping in the
middle lobe. The lung allograft dysfunction occurred 2.8 years after
transplantation, the broncho-alveolar lavage fluid revealed 6.0%
neutrophils. FEV1 had declined to 40% at the start of treatment and
declined further to 30% in the subsequent 6 months. This patient was
judged to have the fibrotic subgroup of bronchiolitis obliterans
syndrome, probably representing true obliterative bronchiolitis
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opinion that air trapping is due to irreversible constrictive
bronchiolitis in all patients with bronchiolitis obliterans
syndrome. Apparently the air trapping in NRAD patients
cannot be fully explained by obliterative bronchiolitis and
possibly spasm, plugging or inflammation of the walls of
small airways may be responsible for the reversible air
trapping. Also bronchial dilatation was reversible in some
patients and the dilated bronchi on pre-treatment CT does
not necessarily represent irreversible bronchiectasis in lung
transplant recipients with NRAD [10]. This ‘reversible
bronchiectasis’ phenomenon has also been observed by
others in acute disease [27, 28].
Our study has limitations. First, we did not control for
inspiratory or expiratory levels, other than using breath-
hold instruction by experienced CT technicians. Air
trapping can be masked by insufficient expiration. We
therefore re-evaluated the subjects with improvement in air
trapping scores, which convinced us that air trapping can be
reversible in NRAD subjects, which is not explained by
level of expiration or other factors. Second, we used a
single reader in this study, given the time-consuming nature
of detailed visual scores and the previously described
observer agreement in a different cohort of lung transplant
recipients [11]. The presented findings are fully in line with
our clinical impression and we checked the CTscores of the
subjects with ‘reversible’ air trapping, therefore we have no
doubts about our findings.
In conclusion, post lung transplant patients with
bronchiolitis obliterans syndrome showing recovery of
the lung functional decline with azithromycin treatment
(neutrophilic reversible lung allograft dysfunction
(NRAD)) differ from patients showing no recovery by
more centrilobular abnormalities on thin-section CT
before the start of treatment and by regression of
bronchus dilatation, consolidation and air trapping that
are not seen in non-responders. The optimal diagnostic
strategy for NRAD and the role of CT imaging,
especially centrilobular disease, and neutrophil counts
requires further research. Radiologists could include
neutrophilic reversible allograft dysfunction (NRAD) in
the differential diagnosis of lung transplant recipients with
allograftdysfunctionwhencentrilobularabnormalitieswithor
without a tree-in-bud pattern are seen on thin-section CT.
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